Lipopolysaccharides play a crucial role in activating the immune system, in particular by acting on systemic immune-activated cells to stimulate the production of pro-inflammatory cytokines, and the investigated Immunostimulatory therapies alone include GM-CSF, and although it has been shown to improve clinical indicators, pro-inflammatory therapies aimed at preventing sepsis are currently being investigated (Maldonado et al., 2016; Hall, 2019). The gene discussed is CSF2; the disease is Sepsis.